Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy - ScienceDirect
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. - Abstract - Europe PMC
PDF) Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro
PDF) Early Phase clinical drug development of novel agents: a changing paradigm
E-Learning Metastatic Melanoma Treatment
PDF) Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Future Oncology
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. - Abstract - Europe PMC
PDF) Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
Dabrafenib in the treatment of metastatic or unresectable melanoma
PDF) Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma Share Your Story
Drug-Like Small Molecules That Inhibit Expression of the Oncogenic MicroRNA-21 | ACS Chemical Biology
Major Changes in Systemic Therapy for Advanced Melanoma
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Future Oncology
PDF) Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro
E-Learning Metastatic Melanoma Treatment
ECC 2015 - ecancer
E-Learning Metastatic Melanoma Treatment
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
